Curis, Inc. (CRIS)
| Market Cap | 747.43M |
| Revenue (ttm) | 10.24M |
| Net Income (ttm) | -34.26M |
| Shares Out | 91.55M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,614,285 |
| Open | 8.25 |
| Previous Close | 8.48 |
| Day's Range | 7.83 - 8.43 |
| 52-Week Range | 1.01 - 17.40 |
| Beta | 2.93 |
| Analysts | Buy |
| Price Target | 23.00 (+188.6%) |
| Est. Earnings Date | Nov 9, 2021 |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid ...
Financial Performance
In 2020, Curis, Inc.'s revenue was $10.84 million, an increase of 8.31% compared to the previous year's $10.00 million. Losses were -$29.91 million, -6.95% less than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Curis, Inc. stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 188.58% from the latest price.
News
Why Curis Stock Perked Up in August
The biotech's shares rode the wave of buyout speculation higher last month.
Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass., Sept. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Curis Q2 Earnings
Shares of Curis (NASDAQ:CRIS) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 29.41% year over year to ($0.12), which missed the est...
Curis Reports Second Quarter 2021 Financial Results
LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...
Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., July 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised t...
Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes
LEXINGTON, Mass., June 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact Rober...
Why Curis Fell Off a Cliff on Friday
The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.
Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial
Curis Inc (NASDAQ: CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings w...
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed o...
LEXINGTON, Mass., June 11, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced upd...
Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA
LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...
Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"
LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the ...
Curis to Present at Jefferies Virtual Healthcare Conference
LEXINGTON, Mass., May 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...
New Strong Sell Stocks for May 20th
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
Why Curis Stock Crashed on Thursday
The swoon came shortly after some very good news for the company.
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates
Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndro...
Curis Reports First Quarter 2021 Financial Results
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...
Why Curis (CRIS) Shares Are Surging Today?
Curis Inc (NASDAQ: CRIS) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk mye...
Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Associat...
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
LEXINGTON, Mass., May 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...